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Abstract
Background: We evaluated if the survival benefit of adding rituximab to standard chemotherapy for non-Hodgkin 
lymphoma (NHL) observed in clinical trials has been experienced by an Australian NHL patient population.
Methods: NHL cases diagnosed in 1985-2004 in New South Wales (NSW) were followed-up to the end of 2004. 
Rituximab prescription data were obtained from Medicare Australia. Using a Poisson regression model adjusted for age 
group, sex, NHL subtype and time period (1990-1994, 1995-1999 and 2000-2004), we estimated excess risk of death 
after a diagnosis of NHL. To give context to the survival trend, trends in incidence and mortality were also estimated.
Results: Compared with 1990-1994, after adjusting for age, sex and NHL subtype the relative excess risk of death was 
significantly lower (p < 0.0001) in 1995-1999 (0.89) and 2000-2004 (0.74). A sharp fall in mortality was observed from 
2000 to 2004 (annual percentage change (APC) = -4.7, p = 0.009), while a small but significant rise in incidence was 
seen from 1990 to 2004 (APC = 0.5, p = 0.01). The number of times rituximab was dispensed in NSW increased rapidly 
from 1274 in 1999 to 9250 in 2004.
Conclusion: It is likely that some benefit of adding rituximab to the standard chemotherapy for NHL has been 
experienced at the population level.
Background
The incidence of non-Hodgkin lymphoma (NHL) had
increased substantially in recent decades with smaller
increases in recent years in many western countries
including Australia. The mortality for NHL rose at a sim-
ilar rate, stabilised in the early 1990s and then started to
fall at the end of the 1990s. The survival pattern for NHL
had not changed significantly in over two decades up to
the late 1990s [1] despite attempts to increase the efficacy
of the standard treatment, combination chemotherapy
(CHOP), with the addition of other cytotoxic drugs [2].
Two pivotal clinical trials in the late 1990s showed that
the addition of the monoclonal antibody targeting the
CD20 antigen expressed on almost all malignant B cells,
rituximab, to standard chemotherapy regimens improved
the survival for patients with indolent NHL, and patients
with diffuse large B-cell lymphoma (the two commonest
NHL subtypes) [1].
This revolutionary advance in the treatment of NHL
was introduced in Australia in around 2000 [3,4]. The aim
of this study was to evaluate if the introduction of this
new treatment modality improved the prognosis of NHL
patients in the State of New South Wales (NSW), Austra-
lia.
Methods
Data
Data were obtained from the population-based NSW
Central Cancer Registry, Australia, for cases diagnosed
with a single first primary NHL between 1985 and 2004.
Based on population size, NSW is the largest state com-
prising approximately one-third of the Australian popula-
tion. Notification of cancer has been a statutory
requirement for all NSW public and private hospitals,
radiotherapy departments and nursing homes since 1972,
and for pathology departments since 1985 [5]. Coding for
primary site and NHL subtype was done either by medi-
cal coders in the hospitals that notified the Registry, or by
medical coders in the Registry, who generally assigned
subtype based on pathology and hospital notifications.
The proportion of cases that were histologically verified
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has been relatively constant (>85%) since 1985 [5]. Cases
aged less than 15 years old, or those reported to the Reg-
istry through death certificate only or first identified at
post-mortem were excluded. All eligible cases were
matched to death records from the State Registrar of
Births, Deaths and Marriages and the National Death
Index to determine survival status at 31 December 2004.
We obtained the Pharmaceutical Benefits claims data
representing the number of times rituximab was dis-
pensed including original prescriptions and repeats [6] in
NSW for 1999-2004 from the Medicare Australia website.
The prescription codes for NHL patients only were used
(8293L, 8294M, 8665C and 8666D), so any increase in the
number of claims is directly related to an increase in use
for the treatment of NHL. As rituximab was listed for
subsidisation in mid 1998, we did not include claims data
for that year.
Trends in survival
Relative survival, a means of removing the effect of mor-
tality from other causes [7], was used in this study
because causes of death on death certificates are often
inaccurate [8]. Relative survival is the ratio of the
observed proportion surviving in a group of patients to
the expected proportion that would have survived in a
comparable group of people (with the same distribution
by age and sex) from the general population [9].
Observed survival was estimated by the life table
method [10]. The estimates of the expected survival pro-
portions for each time period (1990-94, 1995-99 and
2000-2004) were derived from the life tables for the gen-
eral population based on all-cause mortality data and the
NSW population by (five-year) age group, sex and calen-
dar year obtained from the Australian Bureau of Statis-
tics. The period method [11] was used to estimate five-
year relative survival for the time periods 1990-1994,
1995-1999, and 2000-2004 using the implementation sug-
gested by Paul Dickman [12]. Period analysis applies left
truncation to retain the survival experience seen in the
period of interest only [11] (in this case, 1990-94, 1995-99
and 2000-2004).
As treatments for NHL depend on histological sub-
types [13] and there are approximately 40 different sub-
types [14], we grouped all subtypes into four broad
groups according to the cell of origin as well as their
response to therapy and overall survival. They are
"aggressive B-cell", "indolent B-cell", "other NHL (mainly
T/NK cells)" and "NHL not otherwise specified (NOS)".
The clinical groups were based on the WHO classifica-
tion for lymphoma [15] and the International Classifica-
tion of Disease-Oncology Third Edition (ICD-O-3) [16].
Cases diagnosed in 1985-2001 were coded according to
ICD-O-2 [17] in the registry; a computer program con-
verted the ICD-O-2 morphology codes into ICD-O-3
morphology codes using a trans-coding table [16]. Cases
diagnosed after 2001 were coded in ICD-O-3 in the regis-
try.
Changes in survival over time may be due to several
factors, so we assessed the effect of period of survival
using multivariable analysis to adjust for confounding
variables [18]. More detailed statistical analysis methods
for relative survival modeling can be found on Paul Dick-
man's website http://www.pauldickman.com/. Briefly, we
estimated the relative excess risk of death (RER) due to
cancer for the 3 periods with 1990-1994 being the refer-
ence period, assuming a Poisson distribution for excess
deaths [19,20]. In the Poisson model, the dependent vari-
able was the number of excess deaths (calculated as the
observed number of deaths minus the expected number
of deaths based on the population death rates) with
explanatory variables being period of survival, age group
at diagnosis (15-44, 45-59, 60-74 and 75+ years), sex, year
of follow-up and subtypes of NHL, and the natural loga-
rithm of the population size as the offset. All explanatory
variables included in the model were categorical. The
RER derived from this model is the ratio of the excess risk
of death in a given period to the reference period of 1990-
1994 after controlling for the other factors included in the
model. A RER smaller than one for a given period indi-
cated that the risk in that period was lower than that for
1990-1994 and vice versa. Ninety-five percent confidence
intervals (CIs) for the RERs were calculated using the
estimated coefficients and standard errors from the Pois-
son model. A two-sided, log-likelihood ratio test with p <
0.05 was taken to indicate statistical significance.
All analyses were conducted using SAS version 9.0, and
the procedure GENMOD was used to fit the models and
assess the prognostic effects of the variables on relative
survival.
Trends in incidence and mortality rates
To estimate trends in incidence and mortality for NHL,
which we report as context for the survival trend, annual
age-sex standardised incidence and mortality rates were
calculated for the NSW resident population for 1990 to
2004. These rates were expressed per 100,000 of the pop-
ulation and age and sex adjusted by the direct method to
the 2001 Australian standard population.
Joinpoint regression analysis [21] was used to identify
points where a distinct change in the direction or steep-
ness of the trends occurred. The software [22] takes trend
data and fits the simplest joinpoint model that the data
allows. The analysis starts with the minimum number of
joinpoints and identifies any distinct change in direction
in the rates and then tests whether the changes are statis-
tically significant. To describe linear trends by period, an
annual percent change (APC) is computed for each of
those trends.Yu et al. BMC Cancer 2010, 10:231
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Results
A total of 18,798 NHL cases were diagnosed in 1990-
2004, with the commonest subtypes being diffuse large B-
cell lymphomas (DLBCL) (5022) followed by small lym-
phocytic lymphoma (SLL)/chronic lymphocytic leukemia
(CLL) (3929). Table 1 shows the NHL subtypes and main
groups and their ICD-O-3 codes.
Table 2 shows the characteristics of the NHL patients
by calendar period.
There was a substantial increase in 5-year relative sur-
vival for patients with NHL from 1990-1994 to 2000-2004
(53.3% vs 62.1%) (Table 3). Compared with the survival
experience of patients in 1990-94, relative excess risk of
death was significantly lower (p < 0.0001) in 1995-99
(RER = 0.89, 95% CI: 0.84-0.94) and 2000-2004 (RER =
0.74, 95% CI: 0.69-0.78) after adjusting for age, sex and
NHL subtype. Table 3 also shows the estimated 5-year
relative survival and relative excess risk of death for levels
of the other covariates included in the Poisson model.
Five-year relative survival in 2000-2004 was higher for
a l l  a g e  g r o u p s  w i t h  t h o s e  v e r y  o l d  ( 7 5 +  y e a r s )  h a v i n g
poorer outcomes (Figure 1).
Five-year relative survival in 2000-2004 was higher for
all subtypes except for 'Other NHL' (Figure 2).
The number of times rituximab was dispensed for the
treatment of NHL increased rapidly from 1999 (1274) to
2004 (9250) in NSW (Figure 3).
Table 1: Number of cases by subtype of non-Hodgkin lymphoma with groups according to the WHO classification, 1990-
2004 NSW, Australia.
Subtypes and groups ICD-O-3 codes No. of cases
Aggressive B-cell lymphomas
Follicular lymphoma, grade 3 9698 179
Malignant lymphomas (ML), mixed small 
& large cell, diffuse
9675 466
Diffuse large B-cell lymphoma 9678-9680, 9684 5022
Burkitt's lymphoma 9687, 9826 179
Lymphoblastic lymphoma 9728, 9836 11
Indolent B-cell lymphomas
Follicular lymphomas (grade 1 and 2) 9690-9691, 9695 2558
Marginal zone lymphoma of mucosa-
associated lymphoid tissue (MALT)
9689, 9699 302
Small lymphocytic lymphoma, Chronic 
lymphocytic leukemia
9670, 9823 3929
Hairy cell leukemia 9940 277
Lymphoplamacytic lymphomas 9671, 9761 472
Other NHL
Mature T-cell lymphomas: peripheral, 
angioimmunoblastic, hepatosplenic 
gamma/delta T-cell
9702, 9705, 9708, 9714, 9716, 9827 245
Cutaneous T-cell 9709 85
Mycosis fungoides and mantle cell 9700-9701, 9673 422
Other T/NK cell lymphomas 9717, 9718, 9719, 9831, 9948 58
Precursor T-cell 9729, 9837 11
NHL not otherwise specified (NOS)
ML, NOS 9590 1191
ML, non-Hodgkin, NOS 9591 2701
Precursor cell lymphoblastic lymphoma, 
NOS
9727 72
Lymphoid leukemia, NOS 9820 566
Immunoproliferative disease, NOS 9760 32
Precursor cell lymphoblastic leukemia 
NOS
9835 20Yu et al. BMC Cancer 2010, 10:231
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The trends in mortality suggested that a small rise from
1990 to 1996 (APC = 0.8, p = 0.44) was followed by a sub-
stantial but non-significant fall (APC = -2.1, p = 0.41)
from 1996 to 2000 and then a further sharp fall from 2000
to 2004 (APC = -4.7, p = 0.009). There was a small but
significant increase in incidence from 1990 to 2004 (APC
= 0.5, p = 0.02).
Discussion
In this population-based study, we found that a substan-
tial improvement in survival for NHL (5-year relative sur-
vival 62% in 2000-2004 vs 53% in 1990-1994) coincided
with a sharp fall in mortality after 2000. This was approx-
imately when rituximab was approved by the Australian
Therapeutic Goods Administration for clinical use in
Australia for the two commonest NHL subtypes, namely
low grade or follicular lymphoma (June 1998) [3] and dif-
fuse large B-cell lymphomas (February 2002) [4]. These
results are consistent with the beneficial effects of ritux-
imab on cancer survival observed in clinical trials [23-25].
The findings of this population-based study are impor-
tant because it includes all patients with NHL, many of
whom would not have met the trials' inclusion criteria, in
a well-defined geographical area, thus reflecting the expe-
rience of real world everyday clinical practice. The main
strength of the study was that we grouped subtypes of
lymphomas into treatment-based categories classified
according to WHO guidelines. This grouping has been
used by others [26], is clinically useful [27,28] and
reduces the probability of misclassification bias [28].
Another strength is that we studied the trends in the inci-
dence of, survival for and mortality from NHL simultane-
ously, and interpreted the survival trend in the context of
incidence and mortality trends, as recommended by sev-
eral authors [29-31].
What may explain the better survival observed in the
most recent period in this study? Several factors may
have contributed to the improved survival in 2000-2004.
First, high-dose chemotherapy with shorter intervals
between treatment cycles [32], together with better sup-
portive care including antibiotics and growth factor to
manage myelotoxicity [33], was introduced during the
study period. An Australian study has also demonstrated
that growth factor can be used safely and efficaciously to
support intensified chemotherapy (CHOP-14) in Austra-
lian NHL patients [34]. However it only became available
in 2003 and it was dispensed 1560 times in NSW in 2004
[6] so is unlikely to explain the improved survival in 2000-
2004. Second, more NHL patients in NSW may have par-
ticipated in clinical trials [35] which may in part have led
to improved survival in the later period. Third, the intro-
duction of highly active antiretroviral therapy in Australia
around 1997 [36] may explain in part the improved sur-
vival in 2000-2004 [37]. The substantial (although not sig-
nificant) decline (-2.1% per year) in mortality from 1996
to 2000 in our data provides further support for this.
Fourth, changes in case-mix over time may have
accounted for some of the survival benefits observed in
2000-2004. However our use of four broad categories of
lymphoma subtype should reduce this problem to a mini-
Table 2: Characteristics of patients with non-Hodgkin lymphoma, NSW Australia, 1990-2004.
Number of cases Percentage (%)
1990-1994
(n = 5454)
1995-1999
(n = 6231)
2000-2004
(n = 7113)
Sex
Males 10,475 56.3 55.2 55.7
Females 8,323 43.7 44.8 44.3
Age at diagnosis 
(years)
15-44 2,484 15.2 13.2 11.7
45-59 4,110 20.5 21.8 22.9
60-74 6,905 38.0 37.1 35.4
75-89 5,299 26.3 27.9 29.9
NHL groupings
Aggressive B-cell 5,857 32.4 33.3 28.3
Indolent B-cell 7,538 39.5 38.2 42.2
Other NHL 821 1.4 4.1 6.9
NHL NOS 4,582 26.6 24.5 22.5Yu et al. BMC Cancer 2010, 10:231
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mum [28]. As shown in Table 2 the case-mix in different
time periods was generally comparable except for "Other
NHL".
F i n a l l y ,  i n c r e a s i n g  s u r v i v a l  o v e r  t i m e  m a y  r e f l e c t
improvements in earlier detection by screening pro-
grams. However, there is no possibility for early detection
of NHL. Indeed, a small and gradual increase in incidence
was seen from 1990 to 2004, not a sudden substantial
increase in the 2000-2004 period. Therefore, the coinci-
dental sharp fall in mortality from 2000 to 2004 indicates
that these improvements in outcomes were due to effec-
tive therapy [30,31,38]. Indeed, the therapeutic monoclo-
nal antibody, rituximab, was introduced into clinical use
in Australia initially for patients with relapsed or refrac-
tory indolent B-cell NHL (follicular or small lymphocytic
subtypes) in 1998, and then for patients with diffuse large
B - c e l l  l y m p h o m a  ( t h e  c o m m o n e s t  t y p e  o f  a g g r e s s i v e
NHL) in early 2002. The use of rituximab for treating B-
cell NHL has been wide spread in Australia (Figure 3) as
universal health coverage is available and, consistent with
findings from clinical trials, the improved survival was
mainly seen in B-cell lymphomas and was of a similar
magnitude to that reported in the trials [23,39]. It is likely
that these 5-year relative survival estimates in 2000-2004
derived by period analysis underestimate the true later
observed relative survival [40] given the rapid increase in
the use of rituximab for treatment of NHL in Australia.
Taking all this into account, we are reasonably confident
that the introduction of rituximab is a major contributor
to the improved survival observed in 2000-2004.
Our results are also consistent with other population-
based studies examining trends in NHL survival over
time [41,42]. In a recent study using data from the Sur-
veillance, Epidemiology, and End Results (SEER) pro-
gram, Pulte et al found that 5-year relative survival for
NHL patients in the United States improved significantly
between 1990-92 and 2002-2004 (from 50.4% to 66.8%)
[41]. The apparent greater improvement in survival
observed by Pulte et al [41] over the same time period as
our study may be explained by the shorter time intervals
used for their analysis (three years, not five years) with
the greatest benefits from the use of rituximab occurring
in the most recent period. However, the overall consis-
tency of these results with those we reported during an
almost identical study period provides indirect confirma-
tion of our findings. The improved survival in 2000-2004
we observed was also comparable to that of a population-
based study in Canada [42]. However, the magnitude of
the survival improvement that we observed was more
modest. This may be due to the fact that they excluded
patients with poor prognosis such as those who were HIV
positive and those who did not receive curative treatment
Table 3: Five-year relative survival (RSR) and relative excess risk (RER) during the first five years after diagnosis of NHL, 
NSW Australia 1990-2004.
5-yr RSR (%) RER* 95% CI† P-value
Period of survival <0.0001
1990-1994 53.3 1.00
1995-1999 55.9 0.89 (0.84-0.94)
2000-2004 62.1 0.74 (0.69-0.78)
Sex <0.0001
Males 57.5 1.00
Females 57.5 0.86 (0.82-0.91)
Age at diagnosis 
(years)
<0.0001
15-44 66.6 1.00
45-59 70.3 1.03 (0.94-1.13)
60-74 58.3 1.56 (1.44-1.70)
75-89 39.5 2.95 (2.71-3.20)
NHL grouping <0.0001
Agressive B-cell 45.2 1.00
Indolent B-cell 73.1 0.30 (0.28-0.32)
Other NHL 61.0 0.92 (0.86-0.97)
NHL NOS 46.6 0.62 (0.54-0.71)
* Adjusted for all covariates shown in the table using a Poisson regression model
† CI - confidence intervalYu et al. BMC Cancer 2010, 10:231
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[42] whereas our study included all patients with aggres-
sive NHL.
Age at diagnosis was inversely associated with survival
(Figure 1) which is probably due to more co-morbidities
and adverse effects of chemotherapy in older patients.
However, the improved survival over time was seen for
both older and younger patients (Figure 1), although it
was less for those very old (75+ years). This is consistent
with evidence from clinical trials: survival increased for
both older (60-80 years) [23] and younger (18-60 years)
patients [35] after the addition of rituximab to standard
chemotherapy for aggressive B-cell lymphomas, the com-
monest NHL subtype.
The relative survival trends for NHL NOS and aggres-
sive B-cell lymphomas were similar (Figure 2). This sug-
gests that the former group of patients also received
rituximab because previous studies showed that patients
who did not receive cancer-related therapy had poorer
outcomes [43,44]. Improved diagnostic specificity during
the 1990s [45] did not decrease the proportion of NOS
lymphomas over time (Table 2). This is very similar to the
results of a previous study where a SEER registry was
reviewed by an expert hematopathologist (24.3% vs 25%)
[46] and suggests that it may not be possible to decrease
this proportion further on a population-based cancer reg-
istry.
The data used in this study have some limitations. The
cancer registry does not collect detailed treatment infor-
Figure 1 Trends in five-year relative survival for NHL by age 
group at diagnosis, NSW Australia, 1990-2004. Figure 2 Trends in five-year relative survival for NHL by histolog-
ical subtype, NSW Australia, 1990-2004.
Figure 3 Number of times rituximab was dispensed for treatment 
of NHL, NSW Australia, 1999-2004.Yu et al. BMC Cancer 2010, 10:231
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mation and so the data do not allow us to directly con-
clude that the survival benefit observed over time was
due to the use of rituximab in the treatment of NHL,
although the Pharmaceutical Benefits claims data (Figure
3) provided indirect support for the observed improved
survival in 2000-2004. However, these data do not allow
us to estimate the fraction of patients diagnosed in 2000-
2004 who actually used rituximab, thus the possibility
that some unmeasured factors mentioned earlier might
also have contributed to this improved survival cannot be
ruled out completely. Another limitation was that the
cancer registry does not collect information on patients'
comorbidities and disease extent for NHL. These factors
are related to the prognosis for NHL [44]. However, our
use of relative survival to account for competing mortal-
ity addressed these factors at least in part.
Conclusions
The observed rise in survival together with a fall in mor-
tality from 2000 and a rapid increase in the use of ritux-
imab, suggests that the benefit of adding rituximab to the
standard treatment of NHL may have been experienced
at least in part by this Australian NHL patient population.
There are good grounds for believing that further
improvement in survival, especially for patients with
aggressive B-cell lymphomas, will almost certainly con-
tinue to increase as more follow-up time accrues.
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